Authors

Latest:

CAR T-Cell Therapy for Multiple Myeloma: Eliminating Disparities Through Accountability

Although the first FDA approval for CAR T-cell therapy in multiple myeloma was 2 years ago, unfortunately, the treatment remains out of reach for too many patients.

Kelly E. McCann, MD, PhD

Latest:

Looking Ahead: Expert Future Perspectives in the HR+ Breast Cancer Landscape

A panel of experts offer future perspectives in HR+ breast cancer.

Kathleen Lutz, RN, NP-BC WH

Latest:

Advice for New Nurse Practitioners Working With Patients With Endometrial Cancer

Closing their discussion, the panel shares advice for new nurse practitioners caring for patients who have endometrial cancer.

Naval G. Davar, MD

Latest:

Dr Daver on the Initial Safety of DSP-5336 in Relapsed/Refractory Acute Leukemia

Naval G. Daver, MD, discusses updated findings from a phase 1/2 study of the menin-MLL inhibitor DSP-5336 in relapsed/refractory acute leukemias.

Sravanti Rangaraju, MD

Latest:

Student Loan Debt, Immigration Status Often Drive Career Decisions for Fellows

Investigators from Indiana University decided to study some of the factors influencing career plans for physicians, focusing on current fellows and recent graduates of the hematology and medical oncology specialty in the United States.

David Ziegler, MD, PhD

Latest:

Dr Ziegler on Tovorafenib in Pediatric Low-Grade Glioma

David Ziegler, MD, PhD, discusses findings from the phase 2 FIREFLY-1 trial of tovorafenib in pediatric patients with low-grade glioma.

Wade Thomas Iams, MD

Latest:

Dr Iams on the Impact of Adagrasib on Patient Outcomes in KRAS G12C–Mutant NSCLC

Wade T. Iams, MD, discusses the impact of adagrasib on the treatment of patients with KRAS G12C-mutant NSCLC in the second line, as well as its integration into clinical practice.

Samuel Ahuno

Latest:

Ahuno on Bringing Precision Medicine in Cancer Care to Ghana

Samuel Ahuno discusses bringing precision medicine in cancer care to Ghana.

Ashish Manne, MBBS

Latest:

Dr. Manne on the Need for Novel Therapies in HCC Without Preserved Liver Function

Ashish Manne, MBBS, discusses the need to develop novel therapies for patients with hepatocellular carcinoma without preserved liver function.

Raymond Mailhot Vega, MD, MPH

Latest:

Dr Vega on an Analysis of Outcomes with Axillary Surgery in Breast Cancer Post-Neoadjuvant Chemo

Raymond Mailhot Vega, MD, MPH, discusses the efficacy of axillary surgery in patients with breast cancer previously given neoadjuvant chemotherapy, according to findings from a retrospective analysis.

Cynthia Lynch, MD

Latest:

Treating Brain Metastases and the future of HER2+ mBC

Closing out her discussion on HER2+ metastatic breast cancer, Cynthia Lynch, MD, shares her excitement for treatment strategies in the setting of brain metastases.

Fredrik Schjesvold, MD, PhD

Latest:

Dr. Schjesvold on OCEAN Trial Takeaways With Melflufen in Relapsed/Refractory Myeloma

Fredrik Schjesvold, MD, PhD, discusses key takeaways from the phase 3 OCEAN trial that was done in patients with relapsed/refractory multiple myeloma.

Timothy M. Pawlik, MD, PhD, MPH

Latest:

Dr. Pawlik on Advances in Management of mCRC With Liver Metastases

Timothy M. Pawlik, MD, PhD, MPH, discusses advances in the management of patients with metastatic colorectal cancer with liver metastases.

Marc S. Hoffmann, MD

Latest:

Translating BTK Inhibitor Data into Clinical Decision-Making

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, discuss how to use data for BTK inhibitors to inform clinical decisions in chronic lymphocytic leukemia.

Gloria Marquina, MD, PhD

Latest:

Dr Marquina on the Importance of Referring Patients With GIST to Specialized Sarcoma Centers

Gloria Marquina, MD, PhD, as well as the need to consider ongoing clinical trials for patients with gastrointestinal stromal tumors vs treatment with the current second-line standard-of-care agent sunitinib.

John K. Lee, MD, PhD

Latest:

Dr Lee on the Efficacy of Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer

John K. Lee, MD, PhD, discusses the EV-302 trial of frontline enfortumab vedotin plus pembrolizumab in locally advanced or metastatic urothelial cancer.

Pere Barba, MD, PhD

Latest:

Dr. Barba on the Safety of Obecabtagene Autoleucel in Relapsed/Refractory B-ALL

Pere Barba, MD, PhD, discusses the safety of obecabtagene autoleucel in patients with relapsed or refractory B-cell acute lymphoblastic leukemia.

Diana Sutherland, NP

Latest:

Sutherland on the Promise of CDK4 Inhibitors in Metastatic Breast Cancer

Diana Sutherland, NP, discusses the promise of CDK4 inhibitors in patients with metastatic breast cancer.

Zhi Peng, MD

Latest:

Dr Peng on the Efficacy of SHR-1701 Plus Chemotherapy in HER2– Gastric/GEJ Cancer

Zhi Peng, MD, discusses a study of SHR-1701 vs placebo in combination with chemotherapy in the first-line management of HER2– gastric/GEJ adenocarcinoma.

Akriti Jain, MD

Latest:

Dr Jain on the VERONA Study in Higher-Risk MDS

Akriti Jain, MD, discusses the phase 1b VERONA study of venetoclax plus azacitidine in higher-risk myelodysplastic syndromes.